Dosing is underway in a Phase 2b clinical trial, RENEU, evaluating SpringWorks Therapeutics’ (SWTX -3.5%) MEK inhibitor mirdametinib in pediatric and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN) (non-cancerous nerve tumors).
The primary endpoint of the open-label 100-subject
study is response rate up to month 24. The estimated completion date is
July 2022.
https://seekingalpha.com/news/3509140-springworks-launches-mid-stage-study-mirdametinib-nerve-tumors
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.